Cargando…

In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models

Myotonic dystrophy type 1 (DM1) is a rare multisystemic disorder associated with an expansion of CUG repeats in mutant DMPK (dystrophia myotonica protein kinase) transcripts; the main effect of these expansions is the induction of pre-mRNA splicing defects by sequestering muscleblind-like family pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	González, Àlex L., Konieczny, Piotr, Llamusi, Beatriz, Delgado-Pinar, Estefanía, Borrell, José I., Teixidó, Jordi, García-España, Enrique, Pérez-Alonso, Manuel, Estrada-Tejedor, Roger, Artero, Rubén
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459475/ https://www.ncbi.nlm.nih.gov/pubmed/28582438 http://dx.doi.org/10.1371/journal.pone.0178931

Ejemplares similares

Pentamidine rescues contractility and rhythmicity in a Drosophila model of myotonic dystrophy heart dysfunction
por: Chakraborty, Mouli, et al.
Publicado: (2015)

Pyrido[2,3-d]pyrimidin-7(8H)-ones: Synthesis and Biomedical Applications
por: Jubete, Guillem, et al.
Publicado: (2019)

Defined d-hexapeptides bind CUG repeats and rescue phenotypes of myotonic dystrophy myotubes in a Drosophila model of the disease
por: Rapisarda, Anna, et al.
Publicado: (2021)

Modeling of Myotonic Dystrophy Cardiac Phenotypes in Drosophila
por: Chakraborty, Mouli, et al.
Publicado: (2018)

Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy
por: Cerro-Herreros, Estefanía, et al.
Publicado: (2020)

Derepressing muscleblind expression by miRNA sponges ameliorates myotonic dystrophy-like phenotypes in Drosophila
por: Cerro-Herreros, Estefania, et al.
Publicado: (2016)

Increased autophagy and apoptosis contribute to muscle atrophy in a myotonic dystrophy type 1 Drosophila model
por: Bargiela, Ariadna, et al.
Publicado: (2015)

Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes
por: Cerro-Herreros, Estefania, et al.
Publicado: (2017)

Expanding the Diversity at the C-4 Position of Pyrido[2,3-d]pyrimidin-7(8H)-ones to Achieve Biological Activity against ZAP-70
por: Masip, Victor, et al.
Publicado: (2021)

miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models
por: Cerro-Herreros, Estefania, et al.
Publicado: (2018)

Muscleblind, BSF and TBPH are mislocalized in the muscle sarcomere of a Drosophila myotonic dystrophy model
por: Llamusi, Beatriz, et al.
Publicado: (2013)

Six Serum miRNAs Fail to Validate as Myotonic Dystrophy Type 1 Biomarkers
por: Fernandez-Costa, Juan M., et al.
Publicado: (2016)

Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy
por: Chakraborty, Mouli, et al.
Publicado: (2018)

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
por: Cerro-Herreros, Estefanía, et al.
Publicado: (2021)

Pyrido-Fused Deazapurine Bases: Synthesis and Glycosylation of 4-Substituted 9H-Pyrido[2′,3′:4,5]- and Pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyrimidines
por: Veselovská, Lucia, et al.
Publicado: (2020)

Synthesis, Herbicidal Activity, Mode of Action, and In Silico Analysis of Novel Pyrido[2,3-d]pyrimidine Compounds
por: Min, Lijing, et al.
Publicado: (2023)

Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model
por: Overby, Sarah J., et al.
Publicado: (2022)

MicroRNA-Based Therapeutic Perspectives in Myotonic Dystrophy
por: López Castel, Arturo, et al.
Publicado: (2019)

Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression
por: González-Martínez, Irene, et al.
Publicado: (2023)

Synthesis, In Silico Prediction and In Vitro Evaluation of Antitumor Activities of Novel Pyrido[2,3-d]pyrimidine, Xanthine and Lumazine Derivatives
por: El-Kalyoubi, Samar, et al.
Publicado: (2020)

Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents
por: Kumar, Adarsh, et al.
Publicado: (2023)

BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSA(LR) Mice
por: Overby, Sarah J., et al.
Publicado: (2023)

Myotonic dystrophy
por: Patterson, VH
Publicado: (1990)

Myotonic dystrophy type 1 drug development: A pipeline toward the market
por: Pascual-Gilabert, Marta, et al.
Publicado: (2021)

Cancer and Myotonic Dystrophy
por: D’Ambrosio, Eleonora S., et al.
Publicado: (2023)

rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences
por: Sellier, Chantal, et al.
Publicado: (2018)

Deciphering the Complex Molecular Pathogenesis of Myotonic Dystrophy Type 1 through Omics Studies
por: Espinosa-Espinosa, Jorge, et al.
Publicado: (2022)

Quantitative magnetic resonance imaging assessment of muscle composition in myotonic dystrophy mice
por: Bargiela, Ariadna, et al.
Publicado: (2023)

miR-7 Restores Phenotypes in Myotonic Dystrophy Muscle Cells by Repressing Hyperactivated Autophagy
por: Sabater-Arcis, Maria, et al.
Publicado: (2019)

Synthesis and In Silico Docking of New Pyrazolo[4,3-e]pyrido[1,2-a]pyrimidine-based Cytotoxic Agents
por: Horchani, Mabrouk, et al.
Publicado: (2021)

Desflurane anaesthesia in myotonic dystrophy
por: Gandhi, Ranju, et al.
Publicado: (2011)

Myotonic Dystrophy: An Anaesthetic Dilemma
por: Gupta, N, et al.
Publicado: (2009)

Cardiac involvement in myotonic dystrophy
por: Khalighi, Koroush, et al.
Publicado: (2015)

Steakhouse Syndrome in Myotonic Dystrophy
por: Ogasawara, Nobuhiko, et al.
Publicado: (2017)

Cutaneous findings in myotonic dystrophy
por: Kong, Ha Eun, et al.
Publicado: (2022)

6-(2,6-Dimethylphenyl)pyrido[2,3-d]pyrimidin-7-amine
por: Nukui, Seiji, et al.
Publicado: (2009)

Design and Synthesis of a Series of Pyrido[2,3-d]pyrimidine Derivatives as CCR4 Antagonists
por: Gong, Hongwei, et al.
Publicado: (2012)

SnAr Reactions of 2,4-Diazidopyrido[3,2-d]pyrimidine and Azide-Tetrazole Equilibrium Studies of the Obtained 5-Substituted Tetrazolo[1,5-a]pyrido[2,3-e]pyrimidines
por: Leškovskis, Kristaps, et al.
Publicado: (2022)

Pyrido[3,4-d]pyrimidin-4(3H)-one metabolism mediated by aldehyde oxidase is blocked by C2-substitution
por: Hayes, Angela, et al.
Publicado: (2016)

Marathoning with myotonic dystrophy type 2 (proximal myotonic myopathy) and leukopenia
por: Finsterer, Josef, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_la570ciacdelj62ncgm9r25n0b